Form 4: Johnson & Johnson Reports Changes in Beneficial Ownership of CVRx, Inc. Shares
SEC Form 4
Johnson & Johnson reports transactions involving CVRx, Inc. common stock and derivative securities, including warrant exercises and stock option acquisitions, through its subsidiary Johnson & Johnson Innovation JJDC, Inc.
Summary
- Johnson & Johnson, through its subsidiary Johnson & Johnson Innovation JJDC, Inc. (JJDC), reported changes in its beneficial ownership of CVRx, Inc. shares.
- On February 16, 2024, JJDC exercised a warrant to purchase 607,725 shares of CVRx common stock at a price of $0.158 per share.
- The warrant exercise was executed on a cashless basis, resulting in the withholding of 3,725 shares to cover the exercise price, with the remaining 604,000 shares issued to JJDC.
- On February 14, 2024, the warrant was transferred to JJDC from Biosense Webster, Inc., another wholly-owned subsidiary of Johnson & Johnson.
- On February 29, 2024, JJDC acquired additional shares through the exercise of stock options at varying prices, ranging from $0.237 to $5.141.
- These transactions increased JJDC's indirect beneficial ownership of CVRx common stock to 4,103,430 shares.
- Several stock options previously reported as held by JJDC were canceled by CVRx for no value.
Sentiment
Score: 6
Explanation: The document primarily reports transactions related to existing investments. The sentiment is neutral, with a slight positive leaning due to Johnson & Johnson's continued investment in CVRx.
Positives
- Johnson & Johnson's increased stake in CVRx could signal confidence in the company's future prospects.
Negatives
- The cancellation of previously reported stock options held by JJDC could be perceived negatively.
Risks
- The value of CVRx shares could fluctuate, impacting the value of Johnson & Johnson's investment.
- Regulatory or market changes could affect CVRx's business and stock price.
Industry Context
This filing reflects ongoing investment activity in the medical device sector, where Johnson & Johnson Innovation JJDC, Inc. frequently participates through strategic investments and acquisitions.
Comparison to Industry Standards
- Johnson & Johnson's investment in CVRx is typical of large pharmaceutical companies investing in smaller, innovative medical device companies.
- Similar investments can be seen with Medtronic's venture capital arm and Boston Scientific's strategic investments in early-stage companies.
- The size of the warrant exercise and stock option acquisitions is consistent with typical investments made by corporate venture capital arms in the medical device industry.
Stakeholder Impact
- Shareholders of CVRx may view Johnson & Johnson's increased stake as a positive sign.
- The transactions could impact the ownership structure of CVRx.
Key Dates
| Date | Description |
|---|---|
| 02/14/2024 | Warrant was transferred to JJDC from Biosense Webster, Inc. |
| 02/16/2024 | JJDC exercised the warrant to purchase 607,725 shares of Common Stock. |
| 02/29/2024 | JJDC acquired additional shares through the exercise of stock options. |
| 03/06/2024 | Date of the report filing. |
| 11/18/2024 | Expiration date of some stock options. |
| 08/06/2025 | Expiration date of some stock options. |
| 11/09/2025 | Expiration date of some stock options. |
| 02/01/2027 | Expiration date of some stock options. |
| 02/15/2028 | Expiration date of some stock options. |
| 11/28/2028 | Expiration date of some stock options. |
| 12/05/2029 | Expiration date of some stock options. |
| 01/04/2031 | Expiration date of some stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.